

ASX Release

Anatara Lifesciences receives firm commitments for A\$1.0 million in a Successful Placement

Key Highlights

- Firm commitments received for a Placement reflecting strong support from existing institutional and sophisticated investors to raise \$1.0 million (before costs).
- Placement issue price of \$0.04 per new share represents a 3.5% discount to the 15-day volume weighted average price (VWAP) and less than a 5% discount to the 5-day VWAP as at close of trading on 26th April.
- As Stage 2 of Anatara's pivotal GaRP-IBS (Irritable Bowel Syndrome) trial is fully funded and due to report early Q4 CY2024, capital raised from the Placement will be applied to:
 - Refining product development and readiness for commercial manufacturing;
 - Strengthening the balance sheet to:
 - execute potential licensing transaction(s) with pharma companies;
 - appraise new opportunities ; and
 - Working capital purposes.
- Given the unmet need for an effective treatment for IBS, Anatara anticipates strong interest in the ongoing trial of the effectiveness of the Company's patent protected product, known as "GaRP" (from the *G*astrointestinal *R*eProgramming project).
- Stage 2 of the GaRP-IBS trial is the planned extension that follows the successful completion of 61 patients in Stage 1 of the Phase II trial which reported greater than a 50% reduction in IBS symptoms and with safety profile confirmed.
- The Company anticipates updating the market on the progress of recruitment to Stage 2 of the Phase II IBS Clinical Trial in the next quarter.

ADELAIDE, 1 May 2024: Anatara Lifesciences Limited (ASX: ANR or "the Company"), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce it has received firm commitments for a Placement raise a total of \$1.0 million (before costs) (Placement).

The new shares issued under the Placement will fall within the Company's ASX Listing Rule 7.1 and Listing Rule 7.1A capacity. Executive Chair, David Brookes and Non-Executive Director, John Michailidis have committed to take \$60,000 and \$10,000 respectively in the Placement, which will be subject to shareholders' approval at a General Meeting to be convened at a future date to be determined.

As Stage 2 of Anatara's pivotal GaRP-IBS (Irritable Bowel Syndrome) trial is fully funded, capital raised from the Placement will be applied to:

- Refining product development and readiness for commercial manufacturing, and
- Strengthening the balance sheet to progress potential licensing transaction(s) with pharma companies, appraise new opportunities and maintain general working capital.

Stage 2 of the GaRP-IBS trial is the planned extension that follows the successful completion of 61 patients in Stage 1 of the Phase II trial which reported greater than a 50% reduction in IBS symptoms and with safety profile confirmed. With recruitment commencing in April, the final results read-out is expected in early Q4 CY2024.

Anatara's Chair, Dr. David Brookes, commented, *"Given the read-out of Stage 2 of the Pivotal GaRP-IBS trial is expected later in the year, it was critical to ensure Anatara is more than sufficiently capitalised to reach this major milestone and to ensure commercial readiness in the event of a positive trial result confirming efficacy. The strong interest and support shown by our largest shareholders, as sophisticated and institutional investors, meant that only existing shareholders could be involved in this placement. Funds raised will be used to further refine the GaRP product development and the appropriate regulatory processes, thereby ensuring readiness for commercial manufacturing. With the anticipated R&D tax rebate in July 2024, the placement strengthens the Company's balance sheet at a time of ongoing outside corporate interest regarding the global commercialisation of GaRP."*

Placement

The Company will issue a total of 25.0 million New Shares at \$0.04 per share, using the Company's existing capacity under Listing Rule (LR) 7.1 & Listing Rule 7.1A.

20 Million shares are to be allocated under the Company's existing Listing Rule 7.1 and the remaining 5 Million shares under the Company's existing Listing Rule 7.1A. The shares are expected to be issued on Tuesday 7th May 2024.

Taylor Collison Limited acted as Lead Manager and Candour Advisory Pty Ltd acted as Advisor to the Company.

Taylor Collison Limited received 2,000,000 Options with a strike price of 0.10c and a 3-year term for financial services as part of the Placement. These Options will be allocated under the Company's existing Listing Rule 7.1 capacity.

About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's **Gastrointestinal ReProgramming** project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office:

C/-PERKS Level 8, 81 Flinders Street, Adelaide SA 5000

Email: info@anatara.com | Website: anataralifesciences.com